Remarkable success has been achieved in treating various cancer types using immunotherapy targeting the PD1/PDL1 axis [21,22,23,24], which underscores the role of the PD1/PDL1 axis in NK cell responses [25,26]. This evidence concerns the gene CD274 and cancer.